InflaRx N.V.: InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to futility regarding its prespecified primary endpoint (as previously disclosed), ...
Seeking Alpha

CRH plc: S&P 500 Addition Is A Sign Of Maturity, But Valuation Red Flags Emerge

CRH plc is being downgraded to Hold, with a bias toward Sell, despite S&P 500 inclusion and recent record price highs. Revenue growth is modest, margins remain flat, and bottom-line earnings are ...
The New York Times

Lando Norris to use No. 1 in 2026: Why the new F1 champ is taking Verstappen’s number

Lando Norris winning the F1 drivers' championship in Abu Dhabi Clive Rose / Getty Images Just a day after winning his first Formula One world championship, Lando Norris faced a big decision for the ...
MyCentralJersey

Odyssey Announces Addition of Stacy Bogart to Board of Directors

The addition of Ms. Bogart will strengthen Odyssey’s strategic capabilities as it enters its next phase of growth. Odyssey’s decision to expand its Board of Directors underscores the Company’s ...
Reuters

WHO backs use of GLP-1 therapies for obesity, warns access will remain limited

Dec 1 (Reuters) - The World Health Organization on Monday issued its first guideline on the use of GLP-1 therapies for obesity, conditionally recommending them as part of long-term treatment for the ...
ABC News

World Health Organization issues first-ever guidelines for use of GLP-1 weight loss medications

Globally, more than 1 billion people currently live with obesity. The World Health Organization on Monday released new guidance on GLP-1 medications for adults with obesity, recommending their ...
Scientific American

GLP-1 Pill Fails to Slow Alzheimer’s Progression in Clinical Trial

Top-line results from two large clinical trials by Novo Nordisk, the company behind Ozempic and Wegovy, found oral semaglutide failed to slow down Alzheimer's progression Endocrinologist Daniel ...
MarketWatch

The S&P 500’s next addition could be this red-hot tech stock

Cryptocurrency stockpiler Strategy might have an obstacle in its path to S&P 500 inclusion — in the form of an “elephant” currently residing in the S&P Small-Cap 600 index. That’s Stephens analyst ...
The Motley Fool

Meet the Newest Addition to the S&P 500. The Stock Has Soared 200% Since Early Last Year, and Is Still a Buy Right Now, According to 1 Wall Street Analyst.

Emcor is one of the latest entrants to the S&P 500 index. The company's stock has handily outperformed the S&P index in recent years. Robust demand from artificial intelligence (AI) data centers is ...
Yardbarker

Michael Malone praises Warriors addition as perfect complement to Stephen Curry

After a busy offseason, the Golden State Warriors have added several new pieces to their roster as they aim for another championship run. With Jonathan Kuminga’s contract situation finally settled, ...
NPR

Trump defends use of the U.S. military against the 'enemy within'

President Trump defended the use of U.S. troops in American cities and told top U.S. commanders that the military would be used against the "enemy within." "This is going to be a big thing for the ...